Animal Toxins Mimic GLP-1 and Insulin, Modulating Glucagon to Offer Novel Antidiabetic Drug Leads

Maintaining glucose homeostasis is critical, with disruptions leading to type 2 diabetes (T2D), a widespread metabolic disorder. Current treatments often target insulin, glucagon, and incretin hormones like glucagon-like peptide-1 (GLP-1). However, limitations exist in efficacy, side effects, and long-term management. Animal toxins present an underexplored avenue for novel bioactive compounds that can modulate these key glucoregulatory pathways, offering unique mechanisms and high target specificity.

This comprehensive review synthesized existing literature on animal-derived toxins that modulate glucose regulation. Researchers systematically examined compounds that mimic or interfere with the activity of insulin and GLP-1, as well as those that disrupt glucagon signaling. The review focused on the pharmacological relevance of these naturally evolved molecules, discussing their unique mechanisms of action and high target specificity as potential leads for drug development in type 2 diabetes.

The review identified numerous animal toxins with significant pharmacological relevance to glucose metabolism. These compounds broadly fall into categories that either mimic endogenous glucoregulatory hormones or antagonize their actions. Specifically, toxins were found to:

Directly mimic GLP-1 and insulin activity, enhancing glucose-dependent insulin secretion or promoting glucose uptake in target tissues. Other toxins were shown to interfere with glucagon signaling, effectively reducing hepatic glucose production. Several venom-derived compounds have already demonstrated promise in preclinical and early clinical studies, showcasing their potential as templates for novel antidiabetic therapies. These molecules often exhibit high selectivity for specific receptors or pathways, minimizing off-target effects seen with some conventional drugs.